Partner
Bill has substantial experience with traditional patent litigation in district court and arbitrations, as well as litigating under the Biologics Price Competition and Innovation Act (BPCIA) and litigating Abbreviated New Drug Application (ANDA) cases. He also represents clients before the Patent Trial and Appeal Board (PTAB) of the USPTO, appearing as lead counsel in numerous proceedings. In addition to his contentious work, Bill performs client counseling and opinion work, primarily in areas related to biologics, pharmaceuticals, and DNA sequencing. He has been recognized by LMG Life Sciences as a nominee for General Patent Litigator of the Year in the DC area, as an Intellectual Property: Life Sciences Star, and honored for his contributions in the field of "General Patent Litigation." Bill was also named as a DC IP Star by Managing Intellectual Property and a Leading Patent Litigator in the DC area by Intellectual Asset Management. Benchmark Litigation also recognized Bill as a litigation star.
Bill served at the U.S. Court of Appeals for the Federal Circuit as a law clerk for the Honorable Randall R. Rader and the Honorable Jimmie V. Reyna. He has represented pro bono, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veterans Claims.
Prior to joining Finnegan, Bill conducted post-doctoral research in molecular biology and neuroscience in the laboratory of Nobel Laureate Eric Kandel at Columbia University. He frequently speaks at conferences on issues such as the developing body of law relating to biologics.
AbbVie Inc. et al v. Alvotech hf.
1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee
AbbVie Inc. v. Boehringer Ingelheim International GmbH
Represented AbbVie in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®.
1:17-cv-01065, D. Del., Judge Goldberg
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Represented Eli Lilly in patent litigations involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
1:20-cv-01226, D. Del., Judge Andrews
Sandoz Inc. v. AbbVie Biotechnology, Ltd
IPR2018-00002, -00156, IPR2017 -01824, -02106, -02105, PTAB, Judges Ankenbrand, Hulse, Mitchell
Event
California Lawyers Association 47th IP Institute California Lawyers Association 47th IP Institute
November 2-4, 2023
San Diego
Event
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology Patent Law Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology Patent Law
April 27, 2023
Cambridge
Event
The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies
March 21-22, 2023
Boston
"[Raich] brings a wealth of technical expertise in the life sciences space."
Intellectual Asset Management Patent 1000
"[Raich] brings a wealth of technical expertise in the life sciences space."
Intellectual Asset Management Patent 1000
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Managing Intellectual PropertyAward/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Benchmark LitigationAward/Ranking
Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings
September 21, 2023
LMG Life SciencesPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementPress Release
Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings
September 22, 2022
LMG Life SciencesDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.